Personalizing Cognitive Dysfunction Treatment in Multiple Sclerosis

Anne H. Cross, MD; Lauren B. Krupp, MD


March 16, 2022

The risk and severity of cognitive impairment increases at each disease stage in multiple sclerosis (MS). Despite institutional guidelines and easily administered screening protocols, less than 50% of clinicians test their patients for cognitive dysfunction.

Neurologists Anne Cross and Lauren Krupp discuss early individualized testing for the identification of cognitive decline. Because research does not support an approved pharmacologic treatment for cognitive decline, they focus on nonpharmacologic tools for rehabilitation and present supportive strategies for diet, exercise, and assistive accommodations that prolong independence and cognitive reserve.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.